Explore 3 Stock Ideas & Industry Insights Download Free Report

News

MaxCyte (NASDAQ:MXCT) Stock Eases Back: Key Levels and Catalysts to Watch

● MaxCyte has built aBusinessmost investors never see directly: it supplies the cell-engineering technology that helps biotech companies develop cell and gene therapies.

Vinay Lochav | 10 September 2026

Myriad Genetics (NASDAQ:MYGN) Stock: Analysts Split After a Guidance-Suspending Quarter

Myriad Genetics has become one of 2026's more closely tracked diagnostics turnaround stories, and not for flattering reasons. After a steep share-price decline and a wave of analyst downgrades, the molecular-diagnostics veteran enters the autumn trading near multi-year lows, with investors focused squarely on …

Vinay Lochav | 10 September 2026

MannKind Corporation (NASDAQ:MNKD) Slides: What Investors Need to Know

● Based in Danbury, Connecticut, MannKind develops treatments for endocrine and orphan lung diseases built on its proprietary Technosphere dry-powder inhalation platform.

Vinay Lochav | 10 September 2026

Modular Medical, Inc (NASDAQ:MODD) Goes Quiet: Why It Could Still Be One to Watch in September 2026

● Modular Medical develops the Pivot tubeless insulin patch pump, a wearable system that delivers continuous basal and bolus insulin over a three-day wear period, with a removable reservoir, a disposable battery and smartphone connectivity.

Vinay Lochav | 10 September 2026

Medtronic (NYSE:MDT) Keeps Its Case as a Core Healthcare Holding Into September

Medtronic plc (NYSE:MDT) heads into the back half of 2026 looking less like a name in transition and more like one quietly regaining its footing. A raised fiscal 2027 outlook, delivered alongside a roughly $700 million robotics partnership, gave investors two fresh reasons to …

Nitish Kishor | 10 September 2026

MediWound (NASDAQ:MDWD) Stock Gains Ground: Is It Quietly Building Momentum?

● MediWound has spent 2026 building a quietly compelling case as a specialist in tissue repair and wound care, and its Nasdaq-listed shares reflect that trajectory near $14 with a marketCapitalizationaround $180 million.

Nitish Kishor | 10 September 2026

MDxHealth (NASDAQ: MDXH) Stock Eases Back: Key Levels and Catalysts to Watch

A commercial-stage diagnostics company can post double-digit revenue growth and still find its shares under a dollar, a tension that defines MDxHealth SA (NASDAQ: MDXH) heading into autumn 2026. The Nasdaq-listed molecular diagnostics group has built a growing prostate-cancer testing franchise, yet a sliding …

Nitish Kishor | 10 September 2026

Mangoceuticals (NASDAQ: MGRX) Turns Positive: Why It Belongs on the September 2026 Watchlist

Few small-cap health-tech stories have shifted direction as sharply as Mangoceuticals, Inc. (NASDAQ: MGRX), the telemedicine company now attempting to reinvent itself through a proposed pivot into nuclear technology. As September 2026 unfolds, the Nasdaq-listed men's-health platform is juggling a looming listing-compliance deadline, a …

Nitish Kishor | 10 September 2026

Manhattan Scientifics' (OTC:MHTX) Sudden Move Is Liquidity, Not a New Nanotech Milestone

Manhattan Scientifics, Inc (OTC:MHTX) is the kind of long-lived, technology-focused micro-cap that periodically resurfaces in speculative trading chatter, and the ticker has drawn renewed attention after a sharp move. The framing warrants an important caveat up front: in an over-the-counter name quoted at a …

Nitish Kishor | 10 September 2026

Meihua International (OTC:MHUAF) Stock: A Profitable Device Maker Trading Off the Nasdaq Radar

Meihua International Medical Technologies (OTC:MHUAF) is a name that now sits well off the radar of most U.S. investors, and for good reason. The China-based medical-device manufacturer was pushed off the Nasdaq in late 2025 and now changes hands in the over-the-counter market, where …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…